Non-negative curvature obstructions in cohomogeneity one and the Kervaire spheres

In contrast to the homogeneous case, we show that there are compact cohomogeneity one manifolds, that do not support invariant metrics of non-negative sectional curvature. In fact we exhibit infinite families of such manifolds including the exotic Kervaire spheres. Such examples exist for any codimension of the singular orbits except for the case where both are equal to two, where existence of non-negatively curved metrics is known.Comment: 10 page

Waiwhakareke Restoration Plantings: Establishment of Monitoring Plots 2005-06

Waiwhakareke Natural Heritage Park is being developed to reconstruct native lowland and wetland ecosystems as were once widespread in the Waikato Region. The 60ha Natural Heritage Park is located on the north-west outskirts of Hamilton City and includes a peat lake (Horseshoe Lake) which is surrounded by introduced willow trees. There is some native marginal vegetation around the lake, including rushes and sedges, and an extensive area of gently sloping pasture completes the catchment. The restoration and recreation of the native plant and animal communities is being lead by the Hamilton City Council in partnership with The University of Waikato, Wintec, Nga Mana Toopu o Kirikiriroa Limited Resource Management and Cultural Consultants and Tui 2000 (McQueen 2005; McQueen & Clarkson 2003)

A compendium of Caenorhabditis elegans regulatory transcription factors: a resource for mapping transcription regulatory networks

Background Transcription regulatory networks are composed of interactions between transcription factors and their target genes. Whereas unicellular networks have been studied extensively, metazoan transcription regulatory networks remain largely unexplored. Caenorhabditis elegans provides a powerful model to study such metazoan networks because its genome is completely sequenced and many functional genomic tools are available. While C. elegans gene predictions have undergone continuous refinement, this is not true for the annotation of functional transcription factors. The comprehensive identification of transcription factors is essential for the systematic mapping of transcription regulatory networks because it enables the creation of physical transcription factor resources that can be used in assays to map interactions between transcription factors and their target genes. Results By computational searches and extensive manual curation, we have identified a compendium of 934 transcription factor genes (referred to as wTF2.0). We find that manual curation drastically reduces the number of both false positive and false negative transcription factor predictions. We discuss how transcription factor splice variants and dimer formation may affect the total number of functional transcription factors. In contrast to mouse transcription factor genes, we find that C. elegans transcription factor genes do not undergo significantly more splicing than other genes. This difference may contribute to differences in organism complexity. We identify candidate redundant worm transcription factor genes and orthologous worm and human transcription factor pairs. Finally, we discuss how wTF2.0 can be used together with physical transcription factor clone resources to facilitate the systematic mapping of C. elegans transcription regulatory networks. Conclusion wTF2.0 provides a starting point to decipher the transcription regulatory networks that control metazoan development and function

Assessing language skills in adult key word signers with intellectual disabilities: Insights from sign linguistics

Manual signing is one of the most widely used approaches to support the communication and language skills of children and adults who have intellectual or developmental disabilities, and problems with communication in spoken language. A recent series of papers reporting findings from this population raises critical issues for professionals in the assessment of multimodal language skills of key word signers. Approaches to assessment will differ depending on whether key word signing (KWS) is viewed as discrete from, or related to, natural sign languages. Two available assessments from these different perspectives are compared. Procedures appropriate to the assessment of sign language production are recommended as a valuable addition to the clinician’s toolkit. Sign and speech need to be viewed as multimodal, complementary communicative endeavours, rather than as polarities. Whilst narrative has been shown to be a fruitful context for eliciting language samples, assessments for adult users should be designed to suit the strengths, needs and values of adult signers with intellectual disabilities, using materials that are compatible with their life course stage rather than those designed for young children

The mission oriented terminal area simulation facility

The Mission Oriented Terminal Area Simulation (MOTAS) was developed to provide an ATC environment in which flight management and flight operations research studies can be conducted with a high degree of realism. This facility provides a flexible and comprehensive simulation of the airborne, ground-based and communication aspects of the airport terminal area environment. Major elements of the simulation are: an airport terminal area environment model, two air traffic controller stations, several aircraft models and simulator cockpits, four pseudo pilot stations, and a realistic air-ground communications network. MOTAS has been used for one study with the DC-9 simulator and a series of data link studies are planned in the near future

Gamma-Ray Observations of GRO J1655-40

The bright transient X-ray source GRO J1655-40 = XN Sco 1994 was observed by the OSSE instrument on the Compton Gamma Ray Observatory (GRO). Preliminary results are reported here. The initial outburst from GRO J1655-40 was detected by BATSE on 27 Jul 1994. OSSE observations were made in five separate viewing periods starting between 4 Aug 1994 and 4 Apr 1995. The first, third, and fifth observations are near the peak luminosity. In the second observation, the source flux had dropped by several orders of magnitude and we can only set an upper limit. The fourth observation is a weak detection after the period of maximum outburst. In contrast with other X-ray novae such as GRO J0422+32, the spectrum determined by OSSE is consistent with a simple power law over the full range of detection, about 50 - 600 keV. The photon spectral index is in the range of -2.5 to 2.8 in all of the observations. We set an upper limit on fractional rms variation \u3c5% in the frequency range 0.01 – 60 Hz. No significant narrow or broad line features are observed at any energy

Thermal structure and exhumation history of the Lesser Himalaya in central Nepal

The Lesser Himalaya (LH) consists of metasedimentary rocks that have been scrapped off from the underthrusting Indian crust and accreted to the mountain range over the last ~20 Myr. It now forms a significant fraction of the Himalayan collisional orogen. We document the kinematics and thermal metamorphism associated with the deformation and exhumation of the LH, combining thermometric and thermochronological methods with structural geology. Peak metamorphic temperatures estimated from Raman spectroscopy of carbonaceous material decrease gradually from 520°–550°C below the Main Central Thrust zone down to less than 330°C. These temperatures describe structurally a 20°–50°C/km inverted apparent gradient. The Ar muscovite ages from LH samples and from the overlying crystalline thrust sheets all indicate the same regular trend; i.e., an increase from about 3–4 Ma near the front of the high range to about 20 Ma near the leading edge of the thrust sheets, about 80 km to the south. This suggests that the LH has been exhumed jointly with the overlying nappes as a result of overthrusting by about 5 mm/yr. For a convergence rate of about 20 mm/yr, this implies underthrusting of the Indian basement below the Himalaya by about 15 mm/yr. The structure, metamorphic grade and exhumation history of the LH supports the view that, since the mid-Miocene, the Himalayan orogen has essentially grown by underplating, rather than by frontal accretion. This process has resulted from duplexing at a depth close to the brittle-ductile transition zone, by southward migration of a midcrustal ramp along the Main Himalayan Thrust fault, and is estimated to have resulted in a net flux of up to 150 m^2/yr of LH rocks into the Himalayan orogenic wedge. The steep inverse thermal gradient across the LH is interpreted to have resulted from a combination of underplating and post metamorphic shearing of the underplated units

Superconductivity-enhanced bias spectroscopy in carbon nanotube quantum dots

We study low-temperature transport through carbon nanotube quantum dots in the Coulomb blockade regime coupled to niobium-based superconducting leads. We observe pronounced conductance peaks at finite source-drain bias, which we ascribe to elastic and inelastic cotunneling processes enhanced by the coherence peaks in the density of states of the superconducting leads. The inelastic cotunneling lines display a marked dependence on the applied gate voltage which we relate to different tunneling-renormalizations of the two subbands in the nanotube. Finally, we discuss the origin of an especially pronounced sub-gap structure observed in every fourth Coulomb diamond

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer : a systematic review and overview of reviews

Background: Prophylactic aspirin has been considered to be beneficial in reducing the risks of heart disease and cancer. However, potential benefits must be balanced against the possible harm from side effects, such as bleeding and gastrointestinal (GI) symptoms. It is particularly important to know the risk of side effects when aspirin is used as primary prevention - that is when used by people as yet free of, but at risk of developing, cardiovascular disease (CVD) or cancer. In this report we aim to identify and re-analyse randomised controlled trials (RCTs), systematic reviews and meta-analyses to summarise the current scientific evidence with a focus on possible harms of prophylactic aspirin in primary prevention of CVD and cancer. Objectives: To identify RCTs, systematic reviews and meta-analyses of RCTs of the prophylactic use of aspirin in primary prevention of CVD or cancer. To undertake a quality assessment of identified systematic reviews and meta-analyses using meta-analysis to investigate study-level effects on estimates of benefits and risks of adverse events; cumulative meta-analysis; exploratory multivariable meta-regression; and to quantify relative and absolute risks and benefits. Methods: We identified RCTs, meta-analyses and systematic reviews, and searched electronic bibliographic databases (from 2008 September 2012) including MEDLINE, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, NHS Centre for Reviews and Dissemination, and Science Citation Index. We limited searches to publications since 2008, based on timing of the most recent comprehensive systematic reviews. Results: In total, 2572 potentially relevant papers were identified and 27 met the inclusion criteria. Benefits of aspirin ranged from 6% reduction in relative risk (RR) for all-cause mortality [RR 0.94, 95% confidence interval (CI) 0.88 to 1.00] and 10% reduction in major cardiovascular events (MCEs) (RR 0.90, 95% CI 0.85 to 0.96) to a reduction in total coronary heart disease (CHD) of 15% (RR 0.85, 95% CI 0.69 to 1.06). Reported pooled odds ratios (ORs) for total cancer mortality ranged between 0.76 (95% CI 0.66 to 0.88) and 0.93 (95% CI 0.84 to 1.03). Inclusion of the Women's Health Study changed the estimated OR to 0.82 (95% CI 0.69 to 0.97). Aspirin reduced reported colorectal cancer (CRC) incidence (OR 0.66, 95% CI 0.90 to 1.02). However, including studies in which aspirin was given every other day raised the OR to 0.91 (95% CI 0.74 to 1.11). Reported cancer benefits appeared approximately 5 years from start of treatment. Calculation of absolute effects per 100,000 patient-years of follow-up showed reductions ranging from 33 to 46 deaths (all-cause mortality), 60-84 MCEs and 47-64 incidents of CHD and a possible avoidance of 34 deaths from CRC. Reported increased RRs of adverse events from aspirin use were 37% for GI bleeding (RR 1.37, 95% CI 1.15 to 1.62), between 54% (RR 1.54, 95% CI 1.30 to 1.82) and 62% (RR 1.62, 95% CI 1.31 to 2.00) for major bleeds, and between 32% (RR 1.32, 95% CI 1.00 to 1.74) and 38% (RR 1.38, 95% CI 1.01 to 1.82) for haemorrhagic stroke. Pooled estimates of increased RR for bleeding remained stable across trials conducted over several decades. Estimates of absolute rates of harm from aspirin use, per 100,000 patient-years of follow-up, were 99-178 for non-trivial bleeds, 46-49 for major bleeds, 68-117 for GI bleeds and 8-10 for haemorrhagic stroke. Meta-analyses aimed at judging risk of bleed according to sex and in individuals with diabetes were insufficiently powered for firm conclusions to be drawn. Limitations: Searches were date limited to 2008 because of the intense interest that this subject has generated and the cataloguing of all primary research in so many previous systematic reviews. A further limitation was our potential over-reliance on study-level systematic reviews in which the person-years of follow-up were not accurately ascertainable. However, estimates of number of events averted or incurred through aspirin use calculated from data in study-level meta-analyses did not differ substantially from estimates based on individual patient data-level meta-analyses, for which person-years of follow-up were more accurate (although based on less-than-complete assemblies of currently available primary studies). Conclusions: We have found that there is a fine balance between benefits and risks from regular aspirin use in primary prevention of CVD. Effects on cancer prevention have a long lead time and are at present reliant on post hoc analyses. All absolute effects are relatively small compared with the burden of these diseases. Several potentially relevant ongoing trials will be completed between 2013 and 2019, which may clarify the extent of benefit of aspirin in reducing cancer incidence and mortality. Future research considerations include expanding the use of IPD meta-analysis of RCTs by pooling data from available studies and investigating the impact of different dose regimens on cardiovascular and cancer outcomes